TIDMYGEN
RNS Number : 3121E
Yourgene Health PLC
05 November 2020
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Directorate change
Chief Scientific Officer appointment to drive new product
development roadmap
Manchester, UK - 5 November 2020: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces the
appointment of Dr. Joanne Mason as Chief Scientific Officer as a
director of the Company with immediate effect.
Dr Mason has been director of Research & Development
(non-board position) at Yourgene since joining the Company in
December 2019, leading the development of next generation molecular
diagnostics, particularly in the area of reproductive health.
Dr Mason has been a champion of modernising diagnostics with the
use of genomic technologies, having previously held positions as
Vice President Biodiscovery with Cambridge Epigenetix, where she
led the development of clinical epigenomic technologies and
Director of Sequencing and Sample Acquisition for Genomics England,
where she managed the delivery of samples and whole genome
sequencing for the 100,000 Genomes Project.
She has previously acted as an advisor on the Department of
Health (DOH) Rare Disease Policy Board and Forum the Medicines and
Healthcare products Regulatory Agency (MHRA) Genomics for Diagnosis
Forum and the UK National External Quality Assessment (NEQAS) -
Genomics England Steering Committee, Genomics England Sequencing
Advisory Board and Bioindustry Association (BIA) Genomics Advisory
Committee.
Dr Mason also worked for Oxford University Hospitals NHS
Foundation Trust where she set up and managed a NGS Core facility
leading translational research, offering disease-specific
diagnostic panels and introducing whole genome sequencing into the
diagnostic setting. Prior to this role, Dr Mason managed an NGS
Core facility in Malaysia and led the Comparative Genomics group at
Public Health England studying novel and dangerous pathogens. Dr
Mason holds a PhD from Cambridge in Molecular and Cellular
Biology.
Dr Bill Chang, continues on the Board as a director, in a new
role as Chief Entrepreneur focusing on new scientific
collaborations and business ventures for the Group, and remains a
significant shareholder.
Lyn Rees, CEO of Yourgene, commented: "I am delighted to welcome
Dr Mason to the Board of Yourgene Health. Having worked together
for the past year, we have witnessed the tremendous job she has
done enabling the launch and commercialisation of key products such
as the IONA Nx NIPT Workflow and the Clarigene SARS-CoV-2 test.
Adding Dr Mason's extensive experience within molecular diagnostics
to the Board will help us deliver our new product development
roadmap and further commercial successes."
Other than as set out below, there are no other matters required
to be disclosed pursuant to paragraph (g) of Schedule Two to the
AIM Rules for Companies as regards Dr Joanne Mason's appointment.
Dr Joanne Mason (aged 46) holds 20,700 Ordinary Shares with 750,000
Options.
Current directorships Directorships in the past 5 years
N/A N/A
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which
develops and commercialises genetic products and services. The
group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, for reproductive health and
molecular genetics. The Group's products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, male infertility tests and genetic disease tests.
Yourgene's commercial footprint is already established in the UK,
Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene is also extending its genetic
testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in
Taipei and Singapore, and is listed on the London Stock Exchange's
AIM market under the ticker "YGEN". For more information, visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZMGMMDMGGZZ
(END) Dow Jones Newswires
November 05, 2020 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
